杨咏琪, 李洪亮, 梁景岩. 纳米仿生技术在动脉粥样硬化中的应用研究进展[J]. 实用临床医药杂志, 2022, 26(10): 130-134. DOI: 10.7619/jcmp.20215032
引用本文: 杨咏琪, 李洪亮, 梁景岩. 纳米仿生技术在动脉粥样硬化中的应用研究进展[J]. 实用临床医药杂志, 2022, 26(10): 130-134. DOI: 10.7619/jcmp.20215032
YANG Yongqi, LI Hongliang, LIANG Jingyan. Research progress of nano biomimetic technology in atherosclerosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 130-134. DOI: 10.7619/jcmp.20215032
Citation: YANG Yongqi, LI Hongliang, LIANG Jingyan. Research progress of nano biomimetic technology in atherosclerosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 130-134. DOI: 10.7619/jcmp.20215032

纳米仿生技术在动脉粥样硬化中的应用研究进展

Research progress of nano biomimetic technology in atherosclerosis

  • 摘要: 动脉粥样硬化(AS) 是一种慢性炎症性血管疾病,是冠心病、脑卒中、外周血管疾病等的共同病理基础。纳米技术在AS的诊疗上体现出广阔的应用前景,但普通纳米颗粒易被机体认作异物清除出去,难以靶向递送到病变部位。纳米仿生技术在躲避机体免疫性清除的同时,能提升治疗效果和生物相容性。本文对纳米仿生技术在AS中的研究进展、局限性和前景进行综述,以期为AS的预防和诊疗提供新思路。

     

    Abstract: Atherosclerosis (AS) is a chronic inflammatory vascular disease, which is the common pathological basis of coronary heart disease, stroke and peripheral vascular diseases. Nanotechnology has broad application prospects in the diagnosis and treatment of AS, but ordinary nanoparticle is easy to be recognized and eliminated by the body as foreign bodies, and is difficult to be targeted and delivered to the lesion. Nano biomimetic technology can not only avoid the immune clearance of the body, but also improve the efficacy and biocompatibility. This paper reviewed the research progress, limitations and prospects of nano biomimetic technology in AS, so as to provide new ideas for the prevention, diagnosis and treatment of AS.

     

/

返回文章
返回